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Abstract
Objective: The objective of this selective evidence based medicine review is to determine
whether or not ginkgo biloba is effective in managing the symptoms of ADHD and if it exhibits
lower adverse side effects as compared to the current standard of treatment.
Study Design: Systematic review of three English language studies, two of which were
randomized, double blind, controlled trials (one positive controlled, one placebo controlled), and
one open prospective cohort study, published between 2009-2015.
Data Source: Two randomized, double blind, controlled trials (one positive controlled, one
placebo controlled), and one open prospective cohort study. In one study the group received only
ginkgo biloba as tolerated with no comparison group. In another study, one group received
methylphenidate and ginkgo biloba while the comparison group received methylphenidate and a
placebo. In the final study one group received ginkgo biloba while the comparison group
received methylphenidate. All studies were published in peer reviewed journals and were found
via Medline and Pubmed.
Outcomes Measured: The efficacy and tolerability of ginkgo biloba in the treatment of ADHD
symptoms as well as its side effects. This was measured by an ADHD Rating Scale IV and
FBB-HKS (a German DSM-IV-oriented rating scale for ADHD problems) performed by the
subjects’ parents and teachers, CGAS by the subjects’ parents, and side effects by parents,
subjects, and psychiatrists using a rating scale.
Results: The positive controlled study showed methylphenidate to be significantly more
efficacious than ginkgo biloba, however ginkgo biloba showed fewer adverse side effects. The
placebo controlled study showed ginkgo biloba was effective as an add on therapy to
methylphenidate as compared to methylphenidate and a placebo. The open prospective study
showed that with ginkgo biloba, there was improvement in ADHD symptoms as compared to
baseline, with minimal adverse side effects.
Conclusions: From the studies conducted, ginkgo biloba showed to be inferior to
methylphenidate. However, it was an effective alternative or adjunctive treatment for ADHD
symptoms as compared to no treatment or a placebo. Furthermore, it exhibited minimal adverse
side effects.
Keywords: ADHD; Ginkgo biloba
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common
neuropsychiatric disorders found in children.1 Patients with ADHD are believed to have a deficit
in their executive functions, skills that help people focus, organize, and perform tasks.2 The
frontal lobe of the brain is responsible for these executive functions.2 Symptoms of ADHD
remain constant, however some children grow out it as the brain develops into adulthood.2 For
others though, the symptoms remain in adulthood.
The prevalence of ADHD is on the rise, with the CDC recently reporting that amongst the
general population, 10.2% of children and adolescents in the US have ADHD.3 This means that
practitioners should expect to see this disorder more often amongst their patients. It is believed
that there were an average of 9 million office visits with ADHD as the primary diagnosis in
2009-10.3 By seeing how frequently patients present with this disorder, it makes sense that more
money and resources are being invested in managing ADHD. $38–72 billion is believed to have
been spent on children ages 4-17 in the US with ADHD, most of which was used for education
and healthcare.4 The total cost of all US cases of ADHD is estimated to be between $143 billion
to $266 billion.4
There is still much to be discovered and understood about ADHD. The exact cause is
unknown although ADHD seems to have a genetic component. Strong familial connections have
been shown, in that a child has a 50% chance of having the disorder if one parent has it, and a
30% chance if an older sibling has it.5 It also has been associated with pregnancy issues like low
birth weight, premature birth, and difficult pregnancies as well as mothers who drink alcohol or
smoke tobacco when pregnant.5 It also has been connected with physical trauma of the frontal
lobe of the brain.5 Neurochemical studies have shown that deviations from the normal activity of
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dopaminergic and noradrenergic transmitter function can be found in those with ADHD.6 The
key symptoms of ADHD are inattention, hyperactivity, and impulsivity.1
Currently there are many different choices to help curb the symptoms of ADHD.
Lessening the severity of its symptoms is always the goal, as there is no way to treat or eradicate
ADHD. The first line therapy for the disorder continues to be stimulants like Methylphenidate
and amphetamines.7 These have always been shown to be the most effective treatment option.7
However, stimulants have shown to have adverse side effects like headaches, insomnia,
decreased appetite, mood changes, and weight loss.7 Non-stimulants like atomoxetine and
tricyclic antidepressants have also been used to treat ADHD, and have shown to exhibit fewer
side effects.7 Dietary changes as well as vitamins and supplements have also been used by those
who would like to avoid taking medications.8 Behavior therapy has also been an important
treatment option often used in conjunction with medical treatment, to help increase organization
and help patients understand what environments help them cope better.7
The biggest issue in treating ADHD is finding a treatment that effectively curbs the
symptoms, while exhibiting the fewest adverse side effects. This has pushed patients and
practitioners to research alternative treatment options. One alternative that has become more
popular is ginkgo biloba. Ginkgo biloba is a supplement that is used to help manage the
symptoms of many different disorders and illnesses, including those that effect the brain.
Objective
The objective of this selective evidence based medicine review is to determine whether or
not ginkgo biloba is effective in managing the symptoms of ADHD and if it exhibits lower
adverse side effects as compared to the current standard of treatment.
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Methods
This review assessed three studies, two double blind randomized controlled trials, and
one open prospective cohort study, which recorded and compared the side effects and efficacy of
ginkgo biloba as an oral medication in treating the symptoms of ADHD. In each of these studies,
children between the ages of 6 and 14, that had been previously diagnosed with ADHD, were
included. Ginkgo biloba was the intervention that was evaluated in each of these studies. The
supplement was administered orally and the dosage ranged from 80-240 mg. In one study the
group received only ginkgo biloba as tolerated with no comparison group. In another study, one
group was administered methylphenidate and ginkgo biloba while the comparison group
received methylphenidate and a placebo. In the final study one group received ginkgo biloba
while the comparison group was given methylphenidate. The outcomes measured were the
efficacy and tolerability of ginkgo biloba in the treatment of ADHD symptoms, as well as the
side effects exhibited by ginkgo biloba.
The keywords used in the searches were ADHD and ginkgo biloba. All articles were
published in English in peer reviewed journals between 2009-2015. These studies were searched
and found via Medline and Pubmed. The articles were selected based on their relevance to this
review’s clinical question and if they included patient oriented outcomes. Inclusion criteria for
the participants in the studies were older than 6 and younger than 14, diagnosed with ADHD
according to DSM-IV. Exclusion criteria for the studies were other psychiatric disorders,
comorbidities like hypertension, and other neurologic disorders like seizures. The studies utilized
various statistics including RRI, ARI, NNH, and p-value.
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Table 1: Demographics & characteristics of included studies
Study

#
of
Pts
50

Age
(yrs)

Inclusion
Criteria

Exclusion Criteria

6-14

Newly
diagnosed
with ADHD
as per DSMIV-TR, who
scored at least
1.5 standard
deviations
above the
norm based
on their age
and gender on
the ADHDRS-IV School
Version.

Regimen of
ginkgo T.D.
at a dose of
80-120mg
per day
depending on
weight.

Shakibaei1 Double
(2015)
blind
RCT

66

6-12

Diagnosed
with ADHD
based on the
DSM-IV-TR,
Children’s
Global
Assessment
Scale (CGAS)
score<80.

History/current
4
pervasive
developmental
disorders,
schizophrenia,
other psych
disorders/comorbi
dities, suicide risk,
MR (IQ<70),
significant chronic
medical
conditions, organic
brain disorders,
seizures, drug use,
or
hyper/hypotension.
Mental retardation 6
(IQ£70), Type I
Bipolar disorder,
psychosis,
pervasive
developmental
disorder, organic
brain disease,
seizures, CVD.

Uebel-von
Sandersle
ben8
(2014)

20

6-13

Diagnosed
with ADHD
according to
DSM-IV, who
were
unwilling or
could not
tolerate
methylphenid
ate. All
subjects
attended
regular school
and had an
IQ>80.

Pharmacological
treatment within
the previous 2
weeks, seizure
disorders, other
ADHD-like
disorders, and
other medical
conditions such as
hypertension.

Regimen of
ginkgo biloba
EGb 761at a
dose of 80240mg a day
based on
tolerability

Salehi6
(2010)

Type
Double
blind
RCT

Open
prospec
tive
cohort
study

w/d

0

Interventions

Regimen of
methylphenid
ate at a dose
of 20-30mg +
ginkgo biloba
80-120mg
per day
depending on
weight
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Outcomes Measured
Between the three studies the outcomes measured were the symptoms of ADHD as
defined in the DSM-IV-TR via rating scales, the Children’s Global Assessment Scale (CGAS),
and side effects of the intervention via rating scales. In one study, the participants’ parents
measured their children’s symptoms of ADHD through the ADHD Rating Scale IV. In this
study, side effects were assessed by a psychiatrist. In another study, the participants’ parents and
teachers gauged their children’s symptoms of ADHD via the ADHD Rating Scale IV, CGAS
was performed by the subjects’ parents, and side effects were assessed by a psychiatrist. In the
last study, the participants’ attentiveness was assessed by their parents through the FBB-HKS
(part of the Diagnostic System of Mental Disorders in Children and Adolescents [DISYPS-KJ], a
German DSM-IV-oriented rating scale for ADHD problems). Hyperactivity and impulsiveness
were measured by DISYPS-KJ FBB-HKS and FBB-SSV which was performed by the subjects’
parents. Changes in strains on family life were assessed by the FaBel, and changes in the
children’s perceived quality of life were obtained with the KINDL questionnaire. The general
psychopathological profile of the patients was assessed using the German version of the
children’s strengths and difficulties questionnaire (SDQ-D). Side effects were gauged by both
parents and subjects via the Side Effects Rating Scale (SERS-D).
Results
The study by Salehi was a six-week, parallel group, double blind randomized control trial
performed in an outpatient child and adolescent clinic. It was composed of 50 participants
diagnosed with ADHD ages 6-14, of which 39 were males and 11 were females. Subjects were
randomly assigned to either an experimental group (one) or a comparison group (two). Group
one received a ginkgo biloba tablet at a dose of 80–120 mg/day. Dosage was based on weight, 80
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mg/day for those under 30 kg and 120 mg/ day for those over 30 kg. Group two received
methylphenidate at a dose of 20–30 mg/day based on weight, 20 mg/day for those under 30 kg
and 30 mg/day for those over 30kg. No significant difference was found between the two groups
in regards to basic demographic data including gender, age, and ethnicity. Four patients dropped
out, two from each group. Patients were evaluated at days 0, 21, and 42 using the Teacher and
Parent ADHD Rating Scale- IV, which was the primary outcome assessed. Subscales were used
to differentiate change in inattentive and hyperactive-impulsive symptoms. A one-way two-tailed
post-hoc Tukey mean comparison test was performed on the change in Parent and Teacher
ADHD Rating Scale scores from baseline. Results are presented as mean ± SD, and differences
were considered significant with P ≤ 0.05. A Fisher's exact test was used to compare the
frequency of side effects found during the study.
At day zero there was no significant difference between the two groups. At the end of the
six weeks, the parents reported there was a significant change in both the inattentive symptoms
as well as the hyperactive-impulsive symptoms for the experimental and the comparison group
−6.52 ± 11.43 and −15.92 ± 11.44, respectively. The teachers also reported a significant change
in all symptoms for both groups at the six week mark: −0.84 ± 6.79 for the experimental group
and −14.04 ± 8.67 for the comparison group. Ten side effects were noted over the trial, all of
which were deemed mild to moderate and tolerable. All the side effects were found to be more
prevalent in the methylphenidate group. Of those, decreased appetite, insomnia, and headaches
were the only side effects to have showed a significant difference in occurrence between the two
groups. Table 2 shows the incidence of decreased appetite with ginkgo biloba (experimental
event rate of 20%) as compared to Methylphenidate (control event rate of 76%). P-value was
.0002, relative risk increase (RRI) was -74% and absolute risk increase (ARI) was -56%. The
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number needed to harm (NNH) was -17 meaning for every 17 people on ginkgo biloba instead of
methylphenidate, one less patient will suffer from decreased appetite.
Table 2: Incidence of negative outcomes with intervention
CER
EER
RRI
ARI
76%
20%
-74%
-56%

NNH
-17

P-value
0.0002

The study by Shakibaei was a six week randomized, double-blinded, placebo-controlled,
clinical trial with children and adolescents from the ages of 6-12. 66 children were distributed
equally between two groups, with two dropouts coming from the experimental group (due to side
effects) and four coming from the placebo group (one from side effects, two from refusal to
continue, one from lack of response). The dropouts were not significantly different than the other
participants. The experimental group had 19 males and 12 females, and the placebo group had 20
males and 9 females. All participants were given 20-30 mg/day of methylphenidate. Subjects
over 30 kg were given 30 mg, and subjects under 30 were given 20 mg. Dosage was increased
each week by 10 mg up to the assigned dose. Participants in the experimental group received 80120 mg/day of enteric coated tablets of ginkgo biloba. 80 mg/day was given to those with a body
weight of less than 30 kg, and 120 mg/day for those over 30 kg. Dosage was increased each
week by 40 mg up to the assigned dose. Participants in the placebo group received placebo
tablets which were identical in color and size to the ginkgo biloba tablets and were composed of
lactose and starch. No significant difference was found between the two groups in regards to
demographics. Participants were assessed prior to the study and at weeks four and six by parents
and teachers using the ADHD Rating Scale-IV, with subscales for inattention and hyperactivityimpulsivity. Parents completed the CGAS at baseline and at week six, measuring the participants
general psychosocial functioning. Finally, side effects were gauged by a psychiatrist at weeks
two and six. The primary outcome assessed was change in ADHD Rating Scale-IV scores, which

Alge, Ginkgo Biloba and ADHD

8

was considered significant if there was at least a 27% change in baseline, which was derived
from previous studies using this scale. Information was reported as mean ± SD or %. Normal
distribution of quantitative data was checked with the Kolmogorov-Smirnov Test. Group
comparisons were assessed using the Independent Sample t-Test, Manne-Whitney U Test, and
Fisher's Exact Test. A p-value of <0.05 was considered significant in all analyses.
At baseline, no significant difference was found between the two groups in regards to
their disorder. However, significant decreases in both inattentive and hyperactivity-impulsivity
scores were noted for both groups on the ADHD Rating Scale-IV. The parents reported a total
change of -13.1 ± 3.36 and -10.2 ± 3.01 for the experimental and placebo groups, respectively,
with a p-value of .001. The teachers reported a total change of -12.80 ± 5.02 and -11.13 ± 3.43
for the experimental and placebo groups, respectively, with a p-value of .141. There was
significant change in both groups in CGAS, with the experimental increasing by 8.92 ± 7.37, and
the placebo changing by 8.51 ± 5.33. However, there was not a significant difference between
the groups. Several side effects were monitored in both groups, including loss of appetite. Table
3 shows the incidence of decreased appetite in both groups, with it occurring in 24.1% of the
participants in the placebo group and 6.4% of the time in the experimental group. RRI was -73%
and ARI was -17.7%. The NNH was -5 and the P-value was .075. This difference was not
considered significant, and there was no significant difference between any of the side effects in
either group.
Table 3: Incidence of negative outcomes with intervention
CER
EER
RRI
ARI
24.1%
6.4%
-73%
-17.7%

NNH
-5

P-value
.075

The study by Uebel-von Sandersleben was an open prospective clinical cohort study, that
lasted four to five weeks depending on the participant. The study was comprised of 20 subjects,
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15 male and 5 female, ages 6-13. Every subject was started on a dose of 80mg/day of ginkgo
biloba. If attention issues remained present after the first week, then the dose was raised to
120mg/day. For two of the subjects this second dose was effective. The other 18 were raised
again for the third week to 240mg/day. This was an effective dose for the remaining subjects. All
subjects stayed on the determined effective dose for three total weeks, meaning for two patients
the study lasted four weeks total, and for the remaining 18 the study lasted five weeks. No
patients dropped out during the study. The primary outcome of this study was attentiveness of
the patients before and after the intervention. This was assessed through the subjects’ parents and
the use of the FBB-HKS questionnaire, which is a German oriented DSM-IV rating scale for
ADHD problems. This questionnaire was also used to gauge hyperactivity-impulsivity.
Aggressive behavior was evaluated via the FBB-SSV, family life strain was assessed by the
FaBel and the subjects’ quality of life was gauged by the KINDL questionnaire. Each
participant’s psychopathological profile was assessed by the German version of the SDQ-D
questionnaire. Each patient was evaluated before and after the intervention, with pre and
posttreatment behavioral scores being analyzed with a one-sided nonparametric Wilcoxon sign
rank test. Information was reported as mean ± SD.
After the intervention, there proved to be a significant decrease in total symptoms. Table
4 shows the patients’ FBB-HKS Total Score changed -.4±.6, from 1.9±.04 before the
intervention, to 1.5±.7 post treatment. The SDQ-D showed improvement in the subscale of
prosocial behavior (p<.01), but the other subscales of hyperactivity, emotional problems, conduct
problems, and peer problems (all p>.14) remained unchanged. The FBB-SSV showed
improvement in Oppositional-Aggressive symptoms (p<.01), but Dissocial-Aggressive
symptoms were unchanged (p=.25). FaBel showed improvement in family life (p<.01), but the
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KINDL questionnaire showed quality of life remained unchanged (p=.72). The SERS-D showed
lower symptom burden from both parent and participant ratings (p=.05). No serious adverse
reactions were noted during the study, although three mild adverse events were observed in three
patients. These were eosinophilia, allergic dermatitis, and prolonged thrombin time. Each of
these was thought to be unrelated to the ginkgo biloba. In total, the incidence of adverse events
was 0.004 per observation.
Table 4: Efficacy of ginkgo biloba
Study
Pretreatment Score Posttreatment Score Total Change
FBB-HKS Total Score 1.9±.04
1.5±.7
-.4±.6

P- Value
<.01

Discussion
As with any study, there are always limitations. Each study tested the efficacy of ginkgo
biloba in a different way, so each individual study had its own unique shortcomings. For each
study, they could have lasted longer and used a larger sample size. This would have provided a
firmer understanding of the effects of the drugs, and could have answered questions about the
drug’s efficacy over an extended period of time. Another issue was that the subjects were only
children and adolescents. It would be interesting to see if the population sample could have been
compared by age to see if there were any changes in efficacy or side effects.
Currently ginkgo biloba is classified as a supplement in the US, is regulated by the Food
and Drug Administration (FDA), and is available for purchase.9 More often than not, people pay
out of pocket for supplements, as insurance companies avoid covering alternative medicines
when possible.10 Usually, a supplement needs to have been proven efficacious and safe before an
insurance company will cover it.10 Currently, ginkgo biloba is most commonly used by people
who want to help increase their brain function or memory.9 Though at this time, the FDA has not
approved ginkgo biloba for treatment of any medical condition.9
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Conclusions
In conclusion, the goal of this review was to discern if ginkgo biloba is effective in
managing the symptoms of ADHD and if it exhibited lower adverse side effects as compared to
the current standard of treatment. While the evidence brought from these studies is far from
conclusive, it appears that ginkgo biloba is not as effective as the current standard of treatment.
Despite this, there is still some benefit to be had by it, as well as the fact that the patients who
took ginkgo biloba often suffered less side effects. A new area to expand this research would be
to compare ginkgo biloba to some of the second or third line treatment options, specifically the
non-stimulants. It might be there that we find both interventions to be at a similar level of
efficacy.
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